AGENDA

OPEN SESSION
Venue: Hilton Montreal Bonaventure Hotel, Montreal
Room: Salon Verriere
Date: Saturday, April 29th, 2006
Time: 3:00 pm – 4:30 pm
Chair: Dr. Malcolm Moore

3:00 pm WELCOME AND INTRODUCTION  
Dr. M. Moore

3:05 pm UPDATE OF RECENTLY CLOSED TRIALS

PAC.1 (SWOG-S0205): A Randomized Placebo Controlled Study of Cetuximab plus Gemcitabine in Patients with Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

PAC.2 (ECOG-E4201): A Randomized Phase III Study of Gemcitabine in Combination with Radiation Therapy versus Gemcitabine Alone in Patients with Localized, Unresectable Pancreatic Cancer

PA.4: A Phase III, Multi-centre, Double-Blind, Placebo-Controlled Study of AMG 706 plus Gemcitabine and Erlotinib in Patients with Unresectable Locally Advanced or Metastatic Pancreatic Cancer

3:15 pm UPDATE OF ACTIVE TRIALS  
Dr. M. Moore

PA.2 (ESPAC-3): Adjuvant Chemotherapies in Resectable Pancreatic Cancer.

3:20 pm UPDATE OF STUDIES AVAILABLE ON CTSU MENU  
Dr. M. Moore

ECOG – E2204: An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation (Capecitabine and Radiation) in Patients with Completely-Resected Pancreatic Carcinoma

3:25 pm NEW PROPOSALS & DISCUSSION

ADJUVANT

LOCALLY ADVANCED/NEoadjuvant

METASTATIC

GI INTERGROUP UPDATE